AXL and neoplasm: Genetic or molecular inhibition of Axl in mouse models of breast [20], ovarian [23], and pancreatic cancers [24] has demonstrated an enhanced anti-tumor immune response and improved efficacy of anti-programmed death 1 (PD1)/programmed death ligand 1 (PD-L1) ICIs.